Veracyte, Inc.
VCYT
शेयरों में रैंक
#4318
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
शेयर मूल्य
$45.86
मार्केट कैप
$3.69B
बदलाव (1 दिन)
2.39%
बदलाव (1 वर्ष)
27.04%
देश
US
व्यापार Veracyte, Inc. (VCYT)
श्रेणी
Healthcare
Veracyte, Inc. (VCYT) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 2.50
Veracyte, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 2.50 है। 2023 के अंत में, कंपनी का P/B अनुपात 1.91 था।
Veracyte, Inc. के लिए 2011 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 2.50 | -3.24% |
| 2024 | 2.58 | 34.57% |
| 2023 | 1.91 | 21.21% |
| 2022 | 1.58 | -38.10% |
| 2021 | 2.55 | -58.76% |
| 2020 | 6.19 | 14.98% |
| 2019 | 5.38 | -7.87% |
| 2018 | 5.84 | -1.88% |
| 2017 | 5.95 | 58.90% |
| 2016 | 3.75 | 2.76% |
| 2015 | 3.64 | -27.86% |
| 2014 | 5.05 | 372.94% |
| 2013 | 1.07 | -97.22% |
| 2012 | 38.38 | 74.05% |
| 2011 | 22.05 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 4.7411 | 89.93% |
US
|
|
| 3.0143 | 20.75% |
US
|
|
| 31.051 | 1,143.88% |
US
|
|
| - | - |
CN
|
|
| 6.6641 | 166.96% |
US
|
